Detalhe da pesquisa
1.
Perturbation of Alphavirus and Flavivirus Infectivity by Components of the Bacterial Cell Wall.
J Virol
; 96(6): e0006022, 2022 03 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-35107376
2.
Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity.
Proc Natl Acad Sci U S A
; 117(43): 26955-26965, 2020 10 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-33037151
3.
Design, synthesis, and lead optimization of piperazinyl-pyrimidine analogues as potent small molecules targeting the viral capping machinery of Chikungunya virus.
Eur J Med Chem
; 264: 116010, 2024 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38104375
4.
Repurposing Drugs for Mayaro Virus: Identification of EIDD-1931, Favipiravir and Suramin as Mayaro Virus Inhibitors.
Microorganisms
; 9(4)2021 Mar 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-33807492
5.
The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model.
EBioMedicine
; 72: 103595, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-34571361
6.
Itraconazole for COVID-19: preclinical studies and a proof-of-concept randomized clinical trial.
EBioMedicine
; 66: 103288, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-33752127
7.
An affinity-enhanced, broadly neutralizing heavy chain-only antibody protects against SARS-CoV-2 infection in animal models.
Sci Transl Med
; 13(621): eabi7826, 2021 Nov 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-34609205
8.
Corrigendum to "itraconazole for COVID-19: Preclinical studies and a proof-of-concept randomized clinical trial Laurens".
EBioMedicine
; 69: 103454, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-34186486